Citations

Clear

634 citation(s) found for "Hall, A".

Formic Acid-Based Direct, On-Plate Testing of Yeast and Corynebacterium Species by Bruker Biotyper Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry
Theel, Elitza S. , Schmitt, Bryan H., Hall, Leslie, Cunningham, Scott A. , Walchak, Robert C., Patel, Robin , Wengenack, Nancy L. , Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | July 4, 2012 | Volume: 50 | Issue: 9 | Pages: 3093-3095

10.1128/jcm.01045-12 | PMID 22760034 Get It

ABSTRACT An on-plate testing method using formic acid was evaluated on the Bruker Biotyper matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry system using 90 yeast and 78 Corynebacterium species isolates, and 95.6 and 81.1% of yeast and 96.1 and 92.3% of Corynebacterium isolates were correctly identified to the genus and species levels, respectively. The on-plate method using formic acid yielded identification percentages similar to those for the conventional but more laborious tube-based extraction.
Guideline for the diagnosis and management of myelofibrosis
Reilly, John T., Beer, Philip , Butt, Nauman M., Conneally, Eibhlin , Duncombe, Andrew , Green, Anthony R. , Michaeel, N. George, Gilleece, Maria , Hall, Georgina , Knapper, Steven , Mead, Adam J. , Sekhar, Mallika , Wilkins, Bridget S., Harrison, Claire , McMullin, Mary Frances , Mesa, Ruben A. , Mead, Adam J , Knapper, Steven

Mayo Clinic

British Journal of Haematology | June 1, 2012 | Volume: 158 | Issue: 4 | Pages: 453-471

10.1111/j.1365-2141.2012.09179.x | PMID 22651893 Get It

Summary The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK ‐based medical experts, together with a contribution from a single expert from the USA . MEDLINE and EMBASE were searched systematically for publications in E nglish from 1966 until A ugust 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato‐oncology Task Forces of the British Committee for Standards in Haematology ( BCSH ). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH ; the ‘ GRADE ‘ system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post‐polycythaemic myelofibrosis (post‐ PV MF ) and post‐thrombocythemic myelofibrosis (post‐ ET MF ) in both adult and paediatric patients.
Antibody to acetylcholine receptor in myasthenia gravis
LINDSTROM, JON M., Seybold, Marjorie E., Lennon, Vanda A. , Whittingham, Senga, Duane, Drake D. , LINDSTROM, JON M.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 51 | Issue: 4 | Pages: 933

10.1212/wnl.51.4.933-a | PMID 9781505 Get It

Pupillary abnormalities associated with tumors of the pineal region
Seybold, Marjorie E., Yoss, Robert E., Hollenhorst, Robert W., Moyer, Norma J.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 21 | Issue: 3 | Pages: 232-232

10.1212/wnl.21.3.232 | PMID 5314863 Get It

Emetine myopathy
Duane, Drake D. , Engel, Andrew G.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 20 | Issue: 8 | Pages: 733-733

10.1212/wnl.20.8.733 | PMID 4195358 Get It

Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1
Gutmann, David H. , James, C. David , Pöyhönen, Minna , Louis, David N. , Ferner, Rosalie E. , Guha, A. , Hariharan, S., Viskochil, David , Perry, Arie

Mayo Clinic

Neurology | May 13, 2012 | Volume: 61 | Issue: 10 | Pages: 1397-1400

10.1212/wnl.61.10.1397 | PMID 14638962 Get It

Antibody to acetylcholine receptor in myasthenia gravis
Lindstrom, Jon, Seybold, Marjorie E., Lennon, Vanda A. , Whittingham, Senga, Duane, Drake D.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 26 | Issue: 11 | Pages: 1054-1054

10.1212/wnl.26.11.1054 | PMID 988512 Get It

The spectrum and diagnosis of acid maltase deficiency
Engel, Andrew G. , Gómez, Manuel R., Seybold, Marjorie E., Lambert, Edward H.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 23 | Issue: 1 | Pages: 95-95

10.1212/wnl.23.1.95 | PMID 4510595 Get It

The role of genetic breast cancer susceptibility variants as prognostic factors
Fasching, Peter A. , Cox, Angela , Nevanlinna, Heli , Bojesen, Stig E. , Karn, Thomas , Leeuwen, Flora E. van , Veer, Laura van ‘t , Udo, Renate, Dunning, Alison M. , Greco, Dario , Aittomäki, Kristiina, Blomqvist, Carl , Shah, Mitul , Nordestgaard, Børge G. , Flyger, Henrik, Hopper, John L. , Southey, Melissa C. , Apicella, Carmel, García‐Closas, Montserrat , Sherman, Mark E., Lissowska, Jolanta , Seynaeve, Caroline, Huijts, Petra E.A., Tollenaar, Rob A.�E.�M. , Ekici, Arif B. , Rauh, Claudia , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli-Matti, Hartikainen, Jaana M. , Andrulis, Irene L. , Özçelik, Hilmi, Mulligan, Anna Marie , Glendon, Gord, Czene, Kamila , Liu, Jianjun , Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Eilber, Ursula, Nickels, Stefan , Dörk, Thilo , Schiekel, Maria, Bremer, Michael , Park‐Simon, Tjoung‐Won, Giles, Graham G. , Severi, Gianluca , Baglietto, Laura , Hooning, Maartje J. , Jager, Agnes , Kriege, Mieke, Lindblom, Annika , Margolin, Sara , Stevens, Kristen N., Kosel, Matthew , Cross, Simon S. , Balasubramanian, Sabapathy P. , Reed, Malcolm , Miron, Alexander, John, Esther M. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Kauppila, Saila , Burwinkel, Barbara , Schneeweiß, Andreas , Sohn, Christof , Chenevix‐Trench, Georgia , Investigators, kConFab, Lambrechts, Diether , Dieudonné, Anne-Sophie, Hatse, Sigrid , Limbergen, Erik Van, Zamora, M. Pilar , Peissel, Bernard , Loris, Bernard, Peterlongo, Paolo , Rajaraman, Preetha , Beckmann, Matthias W. , Slamon, Dennis J. , Phillips, Kelly‐Anne , Humphreys, Manjeet K., Easton, Douglas F. , Schmidt, Marjanka K. , Thorne, Heather , Purrington, Kristen S. , Lambrechts, Diether , Pharoah, Paul D.P. , Broeks, Annegien , Veer, Laura J. van’t , Ziogas, Argyrios , Mannermaa, Arto, Hall, Per N , Martens, John W.M. , Couch, Fergus J. , Olson, Janet E. , Marmé, Frederik , Investigators, kConFab, Benı́tez, Javier , Milne, Roger L. , Pérez, José Ignacio Arias , Bonanni, Bernardo , Schonfeld, Sara J. , Anton‐Culver, Hoda , Devilee, Peter , Figueroa, Jonine D. , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Peterlongo, Paolo , Lissowska, Jolanta , John, Esther M , Southey, Melissa C , Dunning, Alison M , Lambrechts, Diether , Cox, Angela , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Hartikainen, Jaana M , Chenevix-Trench, Georgia , Czene, Kamila , Pylkäs, Katri , Baglietto, Laura , Bojesen, Stig E , Purrington, Kristen S , Phillips, Kelly-Anne , Lindblom, Annika , Liu, Jing

Mayo Clinic

Human Molecular Genetics | April 25, 2012 | Volume: 21 | Issue: 17 | Pages: 3926-3939

10.1093/hmg/dds159 | PMID 22532573 Get It

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Dispenzieri, Angela , Laumann, Kristina, LaPlant, Betsy, Hayman, Suzanne R. , Kumar, Shaji , Dingli, David , Zeldenrust, Steven R., Hall, Robert L., Rajkumar, S. Vincent , Reeder, Craig B. , Fonseca, Rafaël , Bergsagel, P. Lief, Stewart, A. Keith, Lust, John A., Russell, Stephen J. , Lacy, Martha Q. , Bergsagel, P. Leif , Buadi, Francis K. , Mıkhael, Joseph , Roy, Vivek , Witzig, Thomas E. , Gertz, Morie A. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | April 4, 2012 | Volume: 119 | Issue: 23 | Pages: 5397-5404

10.1182/blood-2012-02-413161 | PMID 22493299 Get It

Abstract Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma. In the present study, we explored the Pom/dex combination in patients with previously treated AL. Patients were eligible for this prospective phase 2 trial if they had had at least one prior regimen and if they had reasonably preserved organ function. Patients were treated with oral Pom/dex. Thirty-three patients were enrolled. The median age was 66 years. Median time from diagnosis to on-study was 37 months. Eighty-two percent had cardiac involvement. The confirmed hematologic response rate was 48%, with a median time to response of 1.9 months. Organ improvement was documented in 5 patients. The median overall and progression-free survival rates were 28 and 14 months, respectively; the 1-year overall and progression-free survival rates were 76% and 59%, respectively. There was a discordance between the hematologic response and the N-terminal pro-brain natriuretic peptide response. The most common grade 3-5 adverse events, regardless of attribution, were neutropenia and fatigue. We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896.